Liminatus Pharma announced its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective August 4, 2026, and that the Nasdaq Hearings Panel granted the company additional time to regain compliance with the minimum bid price requirement. The transfer allows the stock to continue trading on Nasdaq under ticker LIMN, and the Panel gave the company until September 3, 2026 to demonstrate compliance with the Bid Price Rule. Chief Financial Officer Scott Dam said maintaining the Nasdaq listing remains an important priority as the company executes its corporate and clinical development strategy.
Liminatus Pharma, Inc. Class A Common StockTransfer to Nasdaq Capital Market and bid price extension are procedural, not substantive; impact on stock unclear.
